Tech Company Financing Transactions
FesariusTherapeutics Funding Round
FesariusTherapeutics closed a $20 million Series A funding round on 6/10/2026. Backers included Johnson & Johnson Development Corporation and New York Ventures.
Transaction Overview
Company Name
Announced On
6/10/2026
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D efforts.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
619 W 54th St, The Hudson Research Building - 9th Floor
New York, NY 10019
USA
New York, NY 10019
USA
Phone
Undisclosed
Website
Email Address
Overview
FesariusTherapeutics - the cutting-edge biotech start-up on a mission to revolutionize the world of regenerative medicine. We are dedicated to developing innovative tissue-engineered products to transform reconstructive and aesthetic surgery. Founded in 2015, based upon technology spun-out from The Laboratory for Bioregenerative Medicine and Surgery at Weill Cornell Medicine, FesariusTherapeutics has developed DermiSphereTM, a revolutionary dermal regeneration template (DRT) for the management of wounds.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tom Roueche
Chief Scientific Officer
Yulia Sapir-Lekhovitser
Co-Founder
Brett Spector
Founder
Jason Spector
VP - Sales
Tim O'Brien
Browse more venture capital transactions:
Prev: 6/9/2026: fonio.ai venture capital transaction
Next: 6/10/2026: Element Biosciences venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs